Your browser is no longer supported. Please, upgrade your browser.
Settings
GNCA [NASD]
Genocea Biosciences, Inc.
Index- P/E- EPS (ttm)-1.21 Insider Own0.60% Shs Outstand53.02M Perf Week-14.50%
Market Cap124.52M Forward P/E- EPS next Y-0.80 Insider Trans1.49% Shs Float48.03M Perf Month-22.30%
Income-43.70M PEG- EPS next Q-0.20 Inst Own60.50% Short Float3.35% Perf Quarter-3.36%
Sales1.40M P/S88.94 EPS this Y47.90% Inst Trans14.32% Short Ratio2.69 Perf Half Y-8.00%
Book/sh0.17 P/B13.53 EPS next Y0.00% ROA-60.20% Target Price- Perf Year26.37%
Cash/sh1.47 P/C1.56 EPS next 5Y- ROE-358.10% 52W Range1.65 - 5.75 Perf YTD-4.96%
Dividend- P/FCF- EPS past 5Y41.10% ROI-191.80% 52W High-60.00% Beta1.66
Dividend %- Quick Ratio3.30 Sales past 5Y15.20% Gross Margin- 52W Low38.97% ATR0.22
Employees72 Current Ratio3.30 Sales Q/Q- Oper. Margin- RSI (14)34.62 Volatility8.33% 8.10%
OptionableYes Debt/Eq1.72 EPS Q/Q16.40% Profit Margin- Rel Volume1.04 Prev Close2.59
ShortableYes LT Debt/Eq0.00 EarningsFeb 11 BMO Payout- Avg Volume597.58K Price2.30
Recom1.40 SMA20-16.67% SMA50-23.07% SMA200-11.91% Volume621,316 Change-11.20%
Nov-15-19Initiated SVB Leerink Outperform $7
Jul-08-19Resumed Stifel Buy $13
Mar-01-19Reiterated Needham Buy
Feb-06-18Upgrade Needham Hold → Buy $3
Sep-27-17Downgrade Needham Buy → Hold
Sep-26-17Downgrade Stifel Buy → Hold $15 → $2.50
Jul-25-17Upgrade Needham Hold → Buy $12
Feb-17-17Downgrade Needham Buy → Hold
Apr-01-16Reiterated Stifel Buy $11 → $13
Dec-17-15Initiated UBS Buy $15
Oct-20-15Reiterated Needham Buy $22 → $15
Oct-19-15Reiterated FBR Capital Outperform $20 → $17
Mar-05-14Initiated Needham Buy $22
Mar-03-14Initiated Stifel Buy $25
Apr-10-21 08:30AM  
Apr-06-21 04:30PM  
Mar-02-21 04:01PM  
Feb-11-21 07:30AM  
06:30AM  
Feb-04-21 04:05PM  
Jan-28-21 06:00AM  
Jan-19-21 06:54PM  
Jan-04-21 04:19PM  
Dec-28-20 08:42AM  
Dec-21-20 01:24AM  
Dec-10-20 07:54PM  
Nov-12-20 08:00AM  
Nov-09-20 08:01AM  
Nov-05-20 06:10PM  
Oct-29-20 07:00AM  
06:30AM  
Oct-28-20 03:30PM  
Oct-22-20 04:57PM  
09:46AM  
Oct-15-20 11:30AM  
Oct-14-20 05:22PM  
Sep-23-20 11:40AM  
Sep-22-20 09:05AM  
07:30AM  
Sep-17-20 03:00AM  
Sep-15-20 08:07AM  
Sep-03-20 06:53PM  
Jul-30-20 07:00AM  
Jul-23-20 07:00AM  
Jul-22-20 09:02AM  
Jul-20-20 08:00AM  
Jul-16-20 08:00AM  
Jul-06-20 09:27AM  
Jun-23-20 03:52PM  
Jun-22-20 09:00AM  
Jun-15-20 07:30AM  
May-29-20 08:00AM  
May-19-20 07:30AM  
May-13-20 06:02PM  
07:40AM  
May-12-20 05:32PM  
May-11-20 04:30PM  
May-05-20 04:05PM  
Apr-30-20 07:00AM  
Apr-24-20 06:11AM  
Apr-23-20 08:01PM  
11:44AM  
Apr-21-20 07:00AM  
Apr-08-20 04:01PM  
Feb-26-20 04:05PM  
Feb-20-20 09:15PM  
08:00AM  
Feb-13-20 07:00AM  
Feb-06-20 07:30AM  
Dec-14-19 09:43PM  
Nov-14-19 05:00PM  
08:30AM  
Nov-09-19 09:00AM  
Nov-05-19 08:05AM  
Oct-29-19 07:22AM  
Oct-24-19 07:00AM  
Oct-17-19 08:00AM  
Sep-30-19 01:13PM  
Sep-27-19 08:00AM  
Sep-18-19 09:31AM  
Aug-30-19 08:00AM  
Aug-24-19 01:46PM  
Aug-05-19 01:13PM  
Jul-25-19 07:00AM  
Jul-18-19 08:00AM  
Jun-25-19 08:37AM  
Jun-24-19 01:58PM  
Jun-20-19 09:52AM  
Jun-18-19 04:04PM  
Jun-03-19 12:47PM  
10:45AM  
09:17AM  
07:00AM  
May-31-19 12:44PM  
08:00AM  
May-23-19 05:34PM  
May-16-19 01:00PM  
08:00AM  
Apr-30-19 08:13AM  
08:00AM  
Apr-23-19 08:00AM  
Apr-03-19 04:01PM  
Apr-02-19 01:00PM  
Mar-20-19 10:38AM  
Mar-19-19 11:52AM  
Mar-13-19 08:23AM  
Mar-07-19 08:18AM  
Mar-06-19 08:05AM  
Feb-28-19 08:00AM  
Feb-21-19 08:00AM  
Feb-12-19 08:30AM  
Jan-30-19 02:21PM  
Jan-02-19 11:55AM  
08:00AM  
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy using neoantigen-targeted peripheral cells for ATLAS identified anti-tumor antigens that are used to manufacture peripheral blood-derived tumor-specific T cell therapy; and GEN-009, a neoantigen vaccine candidate, delivering adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Clark William DPresident and CEOFeb 17Option Exercise2.2436,49881,78563,750Feb 18 11:25 AM
Clark William DPresident and CEONov 10Buy2.064,7609,8064,760Nov 10 02:45 PM
Sonsini Peter W.10% OwnerJul 24Buy2.253,151,2607,090,33510,376,936Jul 28 05:26 PM
Walker Paul Edward10% OwnerJul 24Buy2.253,151,2607,090,33510,376,936Jul 28 05:26 PM
SANDELL SCOTT D10% OwnerJul 24Buy2.253,151,2607,090,33510,376,936Jul 28 05:25 PM
Makhzoumi Mohamad10% OwnerJul 24Buy2.253,151,2607,090,33510,376,936Jul 28 05:23 PM
MAKOWER JOSHUA10% OwnerJul 24Buy2.253,151,2607,090,33510,376,936Jul 28 05:24 PM
Florence Anthony A. Jr.10% OwnerJul 24Buy2.253,151,2607,090,33510,376,936Jul 28 05:23 PM
Behbahani AliDirectorJul 24Buy2.253,151,2607,090,33510,376,936Jul 28 05:22 PM
Chang Carmen10% OwnerJul 24Buy2.253,151,2607,090,33510,376,936Jul 28 05:22 PM
New Enterprise Associates 16, 10% OwnerJul 24Buy2.253,151,2607,090,33510,376,936Jul 28 05:19 PM
BASKETT FOREST10% OwnerJul 24Buy2.253,151,2607,090,33510,376,936Jul 28 05:20 PM
GLAXOSMITHKLINE PLC10% OwnerJul 24Buy2.251,260,5042,836,1344,626,389Jul 30 08:56 PM